Compare Global X Defense Tech ETF (SHLD) vs Spyre Therapeutics Inc. Common Stock (SYRE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Spyre Therapeutics Inc. Common Stock — how do they compare? Global X Defense Tech ETF trades at $59.75 (market cap $6.34B), while Spyre Therapeutics Inc. Common Stock trades at $78.4 (market cap $7.35B). The key difference: Spyre Therapeutics Inc. Common Stock is the larger of the two by market cap, and Spyre Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 45 Days and Spyre Therapeutics Inc. Common Stock for 0 Days on average.
| SHLD | SYRE | |
|---|---|---|
Market Cap | $6.34B | $7.35B |
Volume | 1,295,513 | 1,624,631 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $108.92 |
52-Week Low | $58.20 | $22.18 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $6.35B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% with a bearish technical outlook as moving averages signal strong selling pressure. The ETF focuses on defense technology and cybersecurity with global diversification beyond U.S. names. Recent institutional buying includes Focus Financial Network increasing its stake by 55.4% in Q2 2026 (SEC filing, August 2026) and Balefire LLC's new $1.12 million position.
Geopolitical tensions and rising global defense budgets support long-term growth potential, though the ETF faces competition from broader aerospace funds and sensitivity to defense policy changes. The current technical weakness near support at $58-59 presents a potential entry point for investors bullish on defense tech innovation.
SYRE trades at $80.45, down 6.34% over 24 hours, with technical indicators showing neutral momentum near key support at $79. The clinical-stage biotech shows no revenue but maintains strong analyst support (92% buy rating) with a $119.89 consensus target. Recent positive SPY003 phase II ulcerative colitis data (Zacks, 2026-09-09) and a $350 million public offering (GlobeNewsWire, 2026-10-05) provide catalysts, though financials reflect pre-revenue challenges with a -197.71% net margin.
Investment outlook balances high-risk, high-reward potential. The robust pipeline in inflammatory bowel disease offers substantial upside if clinical successes continue, but the absence of revenue, negative cash flow from operations, and reliance on financing pose significant risks. Near-term price action will hinge on Q3 2026 earnings and further clinical updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Spyre Therapeutics Inc. Common Stock
Spyre Therapeutics develops extended half-life antibody therapies for inflammatory bowel disease, including ulcerative colitis and Crohn's disease. Its pipeline targets pathways such as α4β7, TL1A, and IL-23 with antibodies engineered for infrequent subcutaneous dosing and potential combination use.
Read more on SYRE →
